[go: up one dir, main page]

MX2009008540A - Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina. - Google Patents

Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.

Info

Publication number
MX2009008540A
MX2009008540A MX2009008540A MX2009008540A MX2009008540A MX 2009008540 A MX2009008540 A MX 2009008540A MX 2009008540 A MX2009008540 A MX 2009008540A MX 2009008540 A MX2009008540 A MX 2009008540A MX 2009008540 A MX2009008540 A MX 2009008540A
Authority
MX
Mexico
Prior art keywords
hcv inhibitors
pyrimidine substituted
compounds
substituted macrocyclic
macrocyclic hcv
Prior art date
Application number
MX2009008540A
Other languages
English (en)
Inventor
Pierre Jean-Marie Bernard Raboisson
Karin Charlotta Lindquist
Anna Karin Gertrud Linnea Belfrage
Horst Juergen Waehling
Karl Magnus Nilsson
Bengt Bertil Samuelsson
Aasa Annica Kristina Rosenquist
Bjoern Olof Classon
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of MX2009008540A publication Critical patent/MX2009008540A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de la fórmula I: (ver fórmula (I)) incluyendo un estereoisómero del mismo, ó un N-óxido, una sal de adición farmacéuticamente aceptable, o un solvato de adición farmacéuticamente aceptable del mismo; útiles como inhibidores de HCV; procedimientos para preparar estos compuestos así como composiciones farmacéuticas que comprenden estos compuestos como ingrediente activo.
MX2009008540A 2007-02-08 2008-02-08 Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina. MX2009008540A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07102005 2007-02-08
PCT/EP2008/051553 WO2008095999A1 (en) 2007-02-08 2008-02-08 Pyrimidine substituted macrocyclic hcv inhibitors

Publications (1)

Publication Number Publication Date
MX2009008540A true MX2009008540A (es) 2009-08-18

Family

ID=39301259

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008540A MX2009008540A (es) 2007-02-08 2008-02-08 Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.

Country Status (13)

Country Link
US (1) US8937080B2 (es)
EP (1) EP2118091B1 (es)
JP (1) JP5554569B2 (es)
KR (1) KR20090110314A (es)
CN (2) CN105254637A (es)
AU (1) AU2008212758B2 (es)
BR (1) BRPI0807087A2 (es)
CA (1) CA2677697A1 (es)
ES (1) ES2541660T3 (es)
HK (1) HK1220455A1 (es)
MX (1) MX2009008540A (es)
RU (1) RU2481340C2 (es)
WO (1) WO2008095999A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
HUE044025T2 (hu) * 2010-05-20 2019-09-30 Array Biopharma Inc Makrociklusos vegyületek mint TRK-kináz inhibitorok
MX2013007698A (es) 2010-12-30 2013-08-15 Abbvie Inc Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina.
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN103387509B (zh) * 2012-05-11 2016-06-08 重庆博腾制药科技股份有限公司 一种hcv蛋白酶抑制剂中间体的制备方法
WO2014062196A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN105164148A (zh) 2013-03-07 2015-12-16 百时美施贵宝公司 丙型肝炎病毒抑制剂
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
PE20180796A1 (es) 2015-10-27 2018-05-09 Hoffmann La Roche Macrociclos peptidicos contra acinetobacter baumannii
KR20180087290A (ko) 2015-11-27 2018-08-01 얀센 사이언시즈 아일랜드 유씨 인플루엔자 바이러스 감염에서 사용하기 위한 복소환식 인돌
JP6989509B2 (ja) * 2016-01-20 2022-01-05 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー インフルエンザウイルス感染における使用のためのアリール置換ピリミジン
EP3388444A1 (en) 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Anti-bacterial peptide macrocycles and use thereof
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100187613B1 (ko) 1992-12-29 1999-06-01 스티븐 에프. 웨인스톡 레트로바이러스성 프로테이제 억제 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
DE69709671T2 (de) 1996-10-18 2002-08-22 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
DE69827956T2 (de) 1997-08-11 2005-04-14 Boehringer Ingelheim (Canada) Ltd., Laval Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
AU769383B2 (en) 1999-03-19 2004-01-22 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
RS51243B (sr) * 2004-01-30 2010-12-31 Medivir Ab. Inhibitori ns-3 serina hcv proteaze
JO2768B1 (en) * 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
PE20070343A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
AR055361A1 (es) * 2005-07-29 2007-08-22 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
KR20090110314A (ko) 2009-10-21
RU2481340C2 (ru) 2013-05-10
BRPI0807087A2 (pt) 2014-06-10
AU2008212758B2 (en) 2014-01-30
EP2118091A1 (en) 2009-11-18
US8937080B2 (en) 2015-01-20
WO2008095999A1 (en) 2008-08-14
HK1220455A1 (zh) 2017-05-05
CA2677697A1 (en) 2008-07-14
RU2009133472A (ru) 2011-03-20
JP2010518048A (ja) 2010-05-27
US20100113440A1 (en) 2010-05-06
CN101641349A (zh) 2010-02-03
CN105254637A (zh) 2016-01-20
AU2008212758A1 (en) 2008-08-14
EP2118091B1 (en) 2015-04-15
JP5554569B2 (ja) 2014-07-23
ES2541660T3 (es) 2015-07-23

Similar Documents

Publication Publication Date Title
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
MX2009008541A (es) Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c.
MX2011011136A (es) Eteres diarilicos.
WO2012030685A3 (en) Indazole derivatives useful as erk inhibitors
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
EA200900135A1 (ru) Производные пиразола в качестве ингибиторов цитохрома р450
SE0400284D0 (sv) Novel compounds
HK1203497A1 (en) Non-systemic tgr5 agonists
UA94833C2 (en) Substituted bicyclolactams
WO2007087548A3 (en) Chemical compounds
WO2008005368A3 (en) Piperazines as p2x7 antagonists
MY148634A (en) Pyridazinone derivatives
WO2007117465A3 (en) Indazole compounds
MY174452A (en) Substituted piperidines that increase p53 activity and the uses thereof
TW200613243A (en) Novel compounds
MY151986A (en) Adamantyl diamide derivatives and uses of same
WO2007084728A3 (en) 2-imino-benzimidazoles
PH12012502216A1 (en) Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienyl-methylbenzene derivatives as inhibitors of sglt
MX2009006334A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona.
TW200806291A (en) Pharmaceutical formulations
WO2007002313A3 (en) Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
WO2009140341A3 (en) Atorvastatin compositions
PT2049480E (pt) Derivados de 2-arilindole como inibidores da mpges-i
TNSN08369A1 (en) Benzimidazole derivatives
WO2012140596A8 (en) Glycoside derivatives and uses thereof

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration